Improved scar in postburn patients following interferon-α2b treatment is associated with decreased angiogenesis mediated by vascular endothelial cell growth factor

Journal of Interferon and Cytokine Research

Volumn 28, Issue 7, 2008, Pages 423-434

  Wang, Jianfei ^a   Chen, Hong ^a   Shankowsky, Heather A ^a   Scott, Paul G ^a   Tredget, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BETA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ANGIOGENESIS; ARTICLE; BURN SCAR; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTROPHIC SCAR; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROBLAST; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; BURNS; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CICATRIX, HYPERTROPHIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 47249100199     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0104     Document Type: Article

References (52)

1. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. 2005. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42(6):1339-1348.
2. Arnold F, West DC. 1991. Angiogenesis in wound healing. Pharmacol Ther 52(3):407-422.
3. Battle TE, Lynch RA, Frank DA. 2006. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 66(7):3649-3657.
4. Belardelli F, Gresser I. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17(8):369-372.
5. Bhatt N, Baran CP, Allen J, Magro C, Marsh CB. 2006. Promising pharmacologic innovations in treating pulmonary fibrosis. Curr Opin Pharmacol 6(3):284-292.
6. Brassard DL, Grace MJ, Bordens RW. 2002. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71(4):565-581.
7. Danese S. 2007. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 23(4):384-389.
8. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9(6):669-676.
9. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, Amento EP. 1990. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol 126(10):1295-1302.
10. Gutterman JU. 1994. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91(4):1198-1205.
11. Harrop AR, Ghahary A, Scott PG, Forsyth N, Uji-Friedland A, Tredget EE. 1995. Regulation of collagen synthesis and mRNA expression in normal and hypertrophic scar fibroblasts in vitro by interferon-gamma. J Surg Res 58(5):471-477.
12. Jaffe EA, Nachman RL, Becker CG, Minick CR. 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52(11):2745-2756.
13. Jakobsson L, Kreuger J, Claesson-Welsh L. 2007. Building blood vessels - stem cell models in vascular biology. J Cell Biol 177(5):751-755.
14. Kalluri R, Sukhatme VP. 2000. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 9(4):413-418.
15. Kang DH, Johnson RJ. 2003. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12(1):43-49.
16. Keane MP, Strieter RM, Lynch JP III, Belperio JA. 2006. Inflammation and angiogenesis in fibrotic lung disease. Semin Respir Crit Care Med 27(6):589-599.
17. Kischer CW, Shetlar MR, Chvapil M. 1982a. Hypertrophic scars and keloids: a review and new concept concerning their origin. Scan Electron Microsc 4:1699-1713.
18. Kischer CW, Thies AC, Chvapil M. 1982b. Perivascular myofibroblasts and microvascular occlusion in hypertrophic scars and keloids. Hum Pathol 13(9):819-824.
19. Larrabee WF Jr, East CA, Jaffe HS, Stephenson C, Peterson KE. 1990. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg 116(10):1159-1162.
20. Lasky JA, Ortiz LA. 2001. Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci 322(4):213-221.
21. Loquai C, Nashan D, Metze D, Beiteke U, Ruping KW, Luger TA, Grabbe S. 2004. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases]. Hautarzt 55(2):176-181.
22. Low QE, Drugea IA, Duffner LA, Quinn DG, Cook DN, Rollins BJ, Kovacs EJ, DiPietro LA. 2001. Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice. Am J Pathol 159(2):457-463.
23. Martin P. 1997. Wound healing - aiming for perfect skin regeneration. Science 276(5309):75-81.
24. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. 2006. Angiogenesis in rheumatoid arthritis. Histol Histopathol 21(5):557-566.
25. Metz CN. 2003. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci 60(7):1342-1350.
26. Mulligan-Kehoe MJ, Simons M. 2007. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 9(2):173-179.
27. Murrell GA, Francis MJ, Bromley L. 1987. Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) 295(6610):1373-1375.
28. Murrell GA, Francis MJ, Howlett CR. 1989. Dupuytren's contracture. Fine structure in relation to aetiology. J Bone Joint Surg Br 71(3):367-373.
29. Nedelec B, Dodd CM, Scott PG, Ghahary A, Tredget EE. 1998. Effect of interferon-alpha2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivo. Wound Repair Regen 6(3):202-212.
30. Nedelec B, Shankowsky H, Scott PG, Ghahary A, Tredget EE. 2001. Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b. Surgery 130(5):798-808.
31. Nedelec B, Shen YJ, Ghahary A, Scott PG, Tredget EE. 1995. The effect of interferon alpha 2b on the expression of cytoskeletal proteins in an in vitro model of wound contraction. J Lab Clin Med 126(5):474-484.
32. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. 2007. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 39(2):212-220.
33. Pestka S, Meager A. 1997. Interferon standardization and designations. J Interferon Cytokine Res 17(Suppl 1):S9-S14.
34. Quesada AR, Munoz-Chapuli R, Medina MA. 2006. Antiangiogenic drugs: from bench to clinical trials. Med Res Rev 26(4):483-530.
35. Sanders JL, Dodd C, Ghahary A, Scott PG, Tredget EE. 1999. The effect of interferon-alpha2b on an in vitro model Dupuytren's contracture. J Hand Surg [Am] 24(3):578-585.
36. Scott PG, Ghahary A, Tredget EE. 1994. Biological basis of hypertrophic scarring. Adv Struct Biol 3:157-201.
37. Scott PG, Ghahary A, Tredget EE. 2000. Molecular and cellular aspects of fibrosis following thermal injury. Hand Clin 16(2):271-287.
38. Shen R, Li TZ, Qi SH, Liang HZ, Xu YB, Xie JL, Wu YF, Feng XS, Du YJ. 2003. [A research of endothelial cell-targeted therapy for cure of hypertrophic scar]. Zhonghua Zheng Xing Wai Ke Za Zhi 19(4):254-257.
39. Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ. 1990. Rating the burn scar. J Burn Care Rehabil 11(3):256-260.
40. Tilg H. 1997. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112(3):1017-1021.
41. Tredget EE. 1999. Pathophysiology and treatment of fibroproliferative disorders following thermal injury. Ann N Y Acad Sci 888:165-182.
42. Tredget EE, Shankowsky HA, Pannu R, Nedelec B, Iwashina T, Ghahary A, Taerum TV, Scott PG. 1998. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast Reconstr Surg 102(5):1317-1328; discussion 1329-1330.
43. Tredget EE, Yang L, Delehanty M, Shankowsky H, Scott PG. 2006. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res 26(3):179-189.
44. Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A. 2000. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res 20(2):143-151.
45. Veale DJ, Fearon U. 2006. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract Res Clin Rheumatol 20(5):941-947.
46. Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. 2007a. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 15(1):113-121.
47. Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. 2007b. Improved scar in post-burn patients after interferon alpha 2b treatment is associated with decreased fibrocytes. J Interferon Cytokine Res 27(11):921-930.
48. Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. 2000. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen 8(2):128-137.
49. Wynn TA. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117(3):524-529.
50. Yang L, Scott PG, Dodd C, Medina A, Jiao H, Shankowsky HA, Ghahary A, Tredget EE. 2005. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 13(4):398-404.
51. Yang L, Scott PG, Giuffre J, Shankowsky HA, Ghahary A, Tredget EE. 2002. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest 82(9):1183-1192.
52. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. 1999. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341(17):1264-1269.